Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 249
- Registration Number
- NCT00652496
Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension
Phase 2
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 111
- Registration Number
- NCT00651859
Study to Evaluate Safety of Brimonidine/Timolol Fixed Combination in Glaucoma or Ocular Hypertension Patients
Phase 3
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- Drug: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic SolutionDrug: Concurrent brimonidine 0.2% and 0.5% timolol
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 604
- Registration Number
- NCT00651612
Safety and Efficacy Study of Brimonidine in Patients With Glaucoma or Ocular Hypertension
Phase 3
Completed
- Conditions
- GlaucomaOcular Hypertension
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Allergan
- Target Recruit Count
- 433
- Registration Number
- NCT00652483
Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers
Phase 2
Completed
- Conditions
- Acute Bacterial Corneal UlcersBacterial Keratitis
- Interventions
- First Posted Date
- 2008-04-03
- Last Posted Date
- 2008-07-29
- Lead Sponsor
- Allergan
- Target Recruit Count
- 129
- Registration Number
- NCT00651586
Safety and Blood Level Study of Unit Dose Budesonide
Phase 1
Completed
- Conditions
- Asthma
- Interventions
- Drug: Budesonide Inhalation SuspensionDrug: MAP0010 low doseDrug: MAP0010 intermediate doseDrug: MAP0010 high dose
- First Posted Date
- 2008-03-03
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 16
- Registration Number
- NCT00627679
- Locations
- 🇦🇺
Q-Pharm Pty Limited, Brisbane, Queensland, Australia
Phase 3 Study of MAP0004 in Adult Migraineurs
Phase 3
Completed
- Conditions
- Migraine Disorders
- Interventions
- Drug: MAP0004Drug: Placebo
- First Posted Date
- 2008-02-26
- Last Posted Date
- 2014-01-09
- Lead Sponsor
- Allergan
- Target Recruit Count
- 902
- Registration Number
- NCT00623636
- Locations
- 🇺🇸
Swedish Pain and Headache Clinic, Seattle, Washington, United States
Surveillance of Ocular Surface Flora (SURFACE)
Completed
- Conditions
- Cataract
- First Posted Date
- 2008-02-22
- Last Posted Date
- 2019-04-26
- Lead Sponsor
- Allergan
- Target Recruit Count
- 399
- Registration Number
- NCT00621933
Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients
Phase 2
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)Drug: Artificial Tears REFRESH ENDURA®
- First Posted Date
- 2008-02-08
- Last Posted Date
- 2011-12-20
- Lead Sponsor
- Allergan
- Target Recruit Count
- 137
- Registration Number
- NCT00611403
Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder
Phase 2
Terminated
- Conditions
- Overactive Bladder
- Interventions
- Biological: botulinum toxin Type A (100U); botulinum toxin Type A (200U)Biological: botulinum toxin Type A (200U)Biological: botulinum toxin Type A (50U); botulinum toxin Type A (200U)Biological: Normal saline (Placebo); botulinum toxin Type A (200U)
- First Posted Date
- 2007-12-17
- Last Posted Date
- 2015-10-02
- Lead Sponsor
- Allergan
- Target Recruit Count
- 74
- Registration Number
- NCT00575016
© Copyright 2025. All Rights Reserved by MedPath